🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ürümqi
Clinical trial register · China

Clinical Trials in Ürümqi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Xinjiang Medical University7 Merck Sharp & Dohme LLC5 Tang-Du Hospital2 First Affiliated Hospital of Zhejiang University2 Second Affiliated Hospital, Zhejiang University, School of Medicine2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Ürümqi

52 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
NCT07589400Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b
DrugACT500
Xiamen Amoytop Biotech Co., Ltd.
Phase 1
24
Beijing, Shanghai, Ürümqi, Xiamen
2026-10-30
Not yet open
Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation
NCT07774897Sleep Disturbance, Fatigue Syndrome, Chronic, Endocrine Disorder, Glucose Metabolism Disorder
Hepatopancreatobiliary Surgery Institute of Gansu Province
Not applicable
400
Lanzhou, Shijiazhuang, Xiangyang, Ürümqi, Kunming
2026-09-30
Not yet open
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
NCT07622394Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology, Cancer Survivorship, Cardiovascular Risk
Xinjiang Medical University
Not applicable
800
Ürümqi
2026-09-01
Recruiting
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NCT07371182Langerhans Cell Histiocytosis (LCH)
DrugLuvometinib
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, Ürümqi
2026-06-19
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
DrugCrisugabalin
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
NCT07499544Chronic Hepatitis D Infection
Huahui Health
Phase 3
160
Changchun, Kashgar, Ürümqi
2026-04-22
Recruiting
Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial
NCT07341932Stable Coronary Artery Disease CAD
Beijing Anzhen Hospital
Not applicable
1,312
Beijing, Chengdu, Ürümqi
2026-03-17
Recruiting
AI Assisted Screening for VHD Using Routine Chest CT Scans
NCT07449130Heart Valve Diseases
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Wuhan, Ürümqi, Hangzhou
2026-03-02
Recruiting
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NCT07431060Langerhans Cell Histiocytosis (LCH)
DrugsMercaptopurine·Luvometinib·Vincristine·Prednisone
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, Ürümqi, Xi'an
2026-02-13
Recruiting
Prognosis of Primary Aldosteronism: A Prospective Cohort Study
NCT07378176Primary Aldosteronism
Xinjiang Medical University
Observational
5,000
Chengdu, Ürümqi
2026-01-30
Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction
NCT07304674Primary Aldosteronism, Cognitive Dysfunction, Mild Cognitive Impairment (MCI), Dementia
Xinjiang Medical University
Observational
1,000
Chengdu, Ürümqi
2025-12-31
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, Ürümqi
2025-12-10
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Chengdu, Guangzhou, Shanghai, Ürümqi
2025-11-06
Recruiting
The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents
NCT07325734CPTSD, Compelx Post-traumatic Stress Disorder
Peking University
Not applicable
130
Fuyang, Beijing, Ulanhot, Ürümqi
2025-10-10
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
182
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, Ürümqi, Linhai
2025-10-08
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming
2025-09-26
Recruiting
"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients
NCT06615609Post Coronary Artery Bypass Grafting, Hypertension, Diabetes Mellitus, Hyperlipidemia
China National Center for Cardiovascular Diseases
Not applicable
536
Ürümqi
2025-09-24
Recruiting
A PAN-USR TB Multi-Center Trial
NCT06905522Pulmonary Tuberculosis
DrugsPretomanid·Sitafloxacin·Bedaquiline·Ethambutol
Shenzhen Third People's Hospital
Phase 3
610
Beijing, Shenzhen, Ürümqi
2025-06-18
Active, closed
The CT-verified Data Collection Study to Investigate the Correlation Between the Leadless Pacemaker Tip Location and Echo, ECG
NCT06910059Bradycardia Sinus, AV Block, Atrial Fibrillation (AF)
Medtronic Cardiac Rhythm and Heart Failure
Observational
40
Ürümqi
2025-06-17
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Guangzhou, Changsha, Changchun, Shanghai, Ürümqi, Hangzhou
2025-06-09
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, Ürümqi
2025-06-01
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869Carcinoma, Non-Small-Cell Lung
DrugAlectinib
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants
NCT06889701Periprosthetic Joint Infection (PJI)
TenNor Therapeutics Inc.
Phase 1/2
33
Ürümqi
2025-04-03
Recruiting
Child-Parent Familial Hypercholesterolemia Screening
NCT04529967Familial Hypercholesterolemia
Children's Hospital of Fudan University
Observational
15,000
Hefei, Qidong, Shanghai, Taiyuan, Chongqing, Ürümqi
2025-04-01
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
NCT06977893HR+/HER2- Breast Cancer
DrugToripalimab
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Recruiting
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
NCT06722586Antiphospholipid (aPL)-Positive, Thrombocytopaenia
DrugsRapamycin·Sirolimus
Peking University First Hospital
Phase 4
84
Changsha, Jinan, Chengdu, Ürümqi, Wenzhou, Beijing, Shanghai
2025-01-07
Not yet open
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Chinese PLA General Hospital
Observational
500
Shenzhen, Wuhan, Changchun, Xi'an, Ürümqi, Hangzhou, Beijing
2024-11
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsLevoleucovorin·Patritumab Deruxtecan·Leucovorin·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
DrugsXelox·Serplulimab
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Not yet open
Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
NCT06580665Non-small Cell Lung Cancer
DrugSerplulimab
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, Ürümqi, Wenzhou
2024-09-01
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, Ürümqi, Wuhan
2024-08-26
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab Deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Recruiting
Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy
NCT06513585Primary Aldosteronism, Suprarenalectomy, Super Selective Adrenal Artery Embolization
Xinjiang Medical University
Not applicable
570
Ürümqi
2024-08-01
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, Ürümqi
2024-07-23
Recruiting
Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography
NCT06520904Coronary Artery Disease, Optical Coherence Tomography
First Affiliated Hospital of Xinjiang Medical University
Phase 4
396
Ürümqi
2024-07-01
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
NCT06611813HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
30
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Shanghai, Ürümqi, Xi'an
2024-06-11
Recruiting
Clinical Outcomes of Cardiovascular Disease
NCT06459934Cardiovascular Diseases, Heart Failure, Coronary Artery Disease
Xinjiang Medical University
Observational
30,000
Ürümqi
2024-06-01
Recruiting
Super Selective Adrenal Artery Embolization for Primary Aldosteronism: a Prospective Cohort Study(SAAE-PA)
NCT06513676Primary Aldosteronism, Super Selective Adrenal Arterial Embolization
Xinjiang Medical University
Observational
500
Ürümqi
2024-04-15
By invitation
The Efficacy and Safety Evaluation of 5G Tele-PCI Using R-OneTM
NCT07132255Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
Cathbot (Shanghai) Robot Co., Ltd
Not applicable
60
Jimsar, Karamay, Kashgar, Luopu, Ürümqi
2024-03-14
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi
2023-12-07
Recruiting
Long-term Success Rate of Transvaginal Mesh for the Treatment of Pelvic Organ Prolapse: The Extended RCT Study
NCT05938881Pelvic Organ Prolapse
Peking Union Medical College Hospital
Observational
336
Foshan, Guangzhou, Changsha, Wuxi, Jinan, Xi’an, Chengdu, Ürümqi
2023-06-29
By invitation
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
NCT05688579Hypertension, Hyperaldosteronaemia
Nanfang Li
Phase 4
8,000
Ürümqi
2023-04-16
Not yet open
Displacement of Iodine Balance Value During Pregnancy and the Mechanism of Breast Iodine Homeostasis During Lactation
NCT05730803Nutritional Requirements
Tianjin Medical University
Observational
1,200
Lanzhou, Ürümqi
2023-02-17
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
Ürümqi, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-12-13
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
DrugBLU-5937
Bellus Health Inc. - a GSK company
Phase 3
997
Kunshan, Leshan, Ürümqi, Beijing, Changsha, Chengdu, Chongqing, Dongguan
2022-12-05
Recruiting
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
NCT05257018Diffuse Large B-cell Lymphoma
Fudan University
Phase 2
83
Shanghai, Ürümqi
2022-02-26
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Dongguan, Fuzhou, Baotou, Nanjing, Nantong, Shanghai, Chengdu, Ürümqi
2020-12-11
Active, closed
Postoperative Thrombosis Prevention in Patients With CD
NCT04486859Cushing Disease, DVT, Pulmonary Embolism
Huashan Hospital
Not applicable
206
Fuzhou, Guangzhou, Wuhan, Shanghai, Chengdu, Ürümqi, Beijing
2020-12-01
Recruiting
Prognostic Model of Hypertension
NCT06160921Hypertension
Xinjiang Medical University
Observational
50,000
Ürümqi
2020-01-01
Recruiting
Tianshan Community Cohort Establishment and Follow-up
NCT07207863Cohort Study, Natural Population, Northwest Region of China
People's Hospital of Xinjiang Uygur Autonomous Region
Observational
1,000,000
Ürümqi
2016-01-01
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
953
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Shanghai, Ürümqi, Wuhan
2015-11-03
Recruiting
China Registry for Genetic / Metabolic Liver Diseases
NCT03131427Genetic/Metabolic Liver Diseases
Beijing Friendship Hospital
Observational
20,000
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Shanghai, Chengdu, Tianjin, Ürümqi
2015-06-13
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/r-mqi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Ürümqi.

How many clinical trials are recruiting in Ürümqi?

33 of the 52 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 10 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ürümqi), 52 studies
PhaseStudiesRecruitingShare
Observational161330.8%
Not applicable12723.1%
Phase 38315.4%
Phase 27413.5%
Phase 4427.7%
Phase 1/2335.8%
Phase 1101.9%
Phase 2/3111.9%

Most active sponsors

Lead sponsors with the most studies (Ürümqi)
Lead sponsorStudiesRecruiting
Xinjiang Medical University76
Merck Sharp & Dohme LLC53
First Affiliated Hospital of Zhejiang University22
Novartis Pharmaceuticals20
Second Affiliated Hospital, Zhejiang University, School of Medicine22
Tang-Du Hospital21
West China Second University Hospital22
AbbVie11
AstraZeneca10
Beijing Anzhen Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.